Clinical Study

An Exploratory Phase II Study To Determine The Tolerability, Safety, And Activity Of A Novel Vasopressin 1A Receptor Antagonist (Srx246) In Irritable Subjects With Huntington's Disease (Hd)

Posted Date: Mar 6, 2017

  • Investigator: Andrew Duker
  • Co-Investigator: Angela Molloy
  • Specialties: Neurology, Movement Disorders
  • Type of Study: Drug

We are doing this research to find out whether a new investigational drug called SRX246, which might be useful to HD patients who sometimes feel irritable, angry, or even aggressive, is well tolerated and safe when it is given two times a day by mouth

Criteria:

We Are Asking You To Take Part In This Research Study Because You Have Huntington's Disease (Hd). Subjects Must Have Clinical Features Of Hd, Which Can Include Motor, Cognitive, Or Behavioral Symptoms. A Confirmatory History Of Hd; Or Cab Repeat Expansion

Keywords:

Huntingtons, Srx246, Neurology, Movement, Null

For More Information:

Molly Winters
513-558-0269
molly.briggs@uc.edu

  • Search Clinical Studies

  • Research in the News

    Targeted Treatment Could Prevent Spread of Pancreatic Cancer, Heart Damage

    Researchers at the UC College of Medicine have shown that a new targetedtreatment could benefit patients with certain pancreatic tumors.